Why was Bharat Biotech Covaxin
Bharat Biotech Covaxin, Some of the major fallbacks of Bharat Biotech’s Covaxin are due to complex processes, dispersed production units, and the need for multiple safe zones. Lack of qualified personnel is also one of the main reasons for the breakdown.
Bharat Biotech Covaxin managing director Dr. Krishna Ella claimed on January 4 that their company is targeting to manufacture 70 crore doses by the end of 2021. Due to the above reasons, they failed to meet the target. So far, 81 crore vaccines have been operated all over India. Since then, only 9.28 crore vaccines are supplied by Bharat Biotech’s Covaxin vaccination drive. The SII has become the poster boy of the vaccination drive by manufacturing 71.50 crore doses, capturing an 88.4% share of the vaccination drive. Sputnik V has also assisted with doses of 8.90 lakh, but its role in the vaccination campaign is negligible.
Not the hero of India’s fight against Covid19
The Union health ministry monitored the production of Bharat Biotech and informed the Supreme Court. They said that Bharat Biotech had failed to reach the promised targets because their average production is only 90 lakh doses per month.
Let me remind you that Covaxin is India’s first indigenous vaccine. Only limited stocks are available. They are India’s most expensive vaccine. Instead of Bharat Biotech Covaxin, Covishield; manufactured by the Pune-based Serum Institute of India (SII), became the hero of the vaccination drive.
In a recent interview with CNBC-TV18, Dr. Ella said that they are working with different companies and will be able to reach a 10 crore figure by the end of the year if all of them deliver as he had expected.